Royalty Pharma

RPRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$67.18

+$1.25 (+1.90%)

At close: Oct 30, 2026, 4:00 PM ET

$67.61

+$0.43 (+0.63%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+1.90%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

60.5

+7.9 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #128/1028 (Top 12%)

Full Analysis

Key Statistics

Market Data

Market Cap $29.91B

1D Range

66.34 67.71

52W Range

37.30 67.70

Valuation (TTM)

PE 38.61

PB 4.38

EV/EBITDA 22.17

Valuation (NTM)

Forward PE 9.01

Forward PEG 1.88

Price Target $66.50

Cash Flow

FCF Yield 9.9%

SBC Adj. FCF Yield 9.3%

SBC Impact -6.7%

Margins

Gross Margin 89.4%

Operating Margin 62.3%

FCF Margin 117.4%

Growth (CAGR)

Revenue 3Y | 5Y 2.4% | 2.5%

Dil EPS 3Y | 5Y 72.3% | 6.8%

FCF 3Y | 5Y 2.7% | 6.9%

Returns

ROA 4.1%

ROE 12.3%

ROIC 9.0%

Financial Health

Net Debt

$8.12B

Current Ratio 1.29

Interest Coverage 4.38

Dividends

Div Yield 1.37%

Payout Ratio 53.2%

FCF Payout Ratio 13.4%

All Key Statistics

Loading financial charts...

Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approxim...

Sector Healthcare

Industry Medical - Pharmaceuticals

Employees 100

IPO Date Jun 16, 2020

Website www.royaltypharma.com

Fiscal Year January - December

Full Company Profile

Latest News

2 days ago · zacks.com

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

3 days ago · fool.com

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release. It's unclear whether the company will knock it out of the park this quarter, as was the case with Q2 2026.

8 days ago · fool.com

Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead

Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development.

11 days ago · fool.com

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Royalty Pharma buys drug royalties. Buying drug royalties provides pharmaceutical companies with cash up front while giving Royalty Pharma a long-term income stream.

17 days ago · globenewswire.com

Royalty Pharma declares fourth quarter 2026 dividend

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.

24 days ago · globenewswire.com

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

25 days ago · zacks.com

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago · fool.com

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.

1 month ago · marketbeat.com

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.